Find out more about REPROCELL’s Clinical iPSCs and MSCs
Reviews
Review article (offsite)
How to find the right end-to-end developer for manufacturing your cGMP-compatible iPSCs
From β-islets for diabetes to dopaminergic neurons for Parkinson’s disease, induced pluripotent stem cell (iPSC)-derived, haplotyped, and multiplex-engineered allogeneic cell therapeutics empower the development of effective and safe Cell and Gene Therapy Products (CGTs) that could be manufactured on a large scale in a cost-effective manner and provide a functional cure for diseases that plague humankind today.
Bioinformant
Review article (offsite)
Making iPSC-derived therapies a clinical reality
Since their invention in 2006, induced pluripotent stem cells (iPSCs) have revolutionized how researchers approach disease modelling, drug discovery research, and drug development. Derived from adult somatic stem cells rather than embryos, iPSCs have allowed scientists to study human biology with increased depth, reproducibility, scalability, and translatability. This is especially true for diseases where animal models lack clinical relevance, and where primary tissues are difficult to access.
Stem Cell Research and Technology